EAM
RARE icon

EFG Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

EFG Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.85M Sell
127,985
-7,865
-6% -$236K 0.5% 87
2025
Q2 		$4.94M Buy
135,850
+12,908
+10% +$465K 0.7% 47
2025
Q1 		$4.45M Sell
122,942
-16,501
-12% -$686K 0.74% 36
2024
Q4 		$5.86M Buy
139,443
+30,055
+27% +$1.49M 0.8% 28
2024
Q3 		$6.07M Sell
109,388
-16,173
-13% -$824K 1.02% 14
2024
Q2 		$5.16M Buy
125,561
+8,725
+7% +$373K 0.89% 21
2024
Q1 		$5.45M Buy
116,836
+48,368
+71% +$2.28M 0.94% 20
2023
Q4 		$3.27M Buy
68,468
+10,547
+18% +$409K 0.62% 60
2023
Q3 		$2.07M Buy
57,921
+4,250
+8% +$168K 0.49% 66
2023
Q2 		$2.48M Sell
53,671
-5,758
-10% -$267K 0.53% 64
2023
Q1 		$2.38M Buy
+59,429
New +$2.55M 0.53% 62

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EFG Asset Management's RARE Position: Q3 2025 in Review

EFG Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 5.8% in Q3 2025, selling an estimated $236K and leaving 127,985 shares worth $3.85M. The position accounts for 0.5% of the portfolio, ranked #87.

EFG Asset Management first reported a position in RARE in Q1 2023 and has held it in 11 quarters since. The position peaked at $6.07M in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • EFG Asset Management held 127,985 shares of Ultragenyx Pharmaceutical worth $3.85M as of Q3 2025.
  • EFG Asset Management sold 7,865 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $236K.
  • Ultragenyx Pharmaceutical made up 0.5% of EFG Asset Management's portfolio in Q3 2025, its #87 holding.
  • EFG Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and has held it in 11 quarters since.
  • EFG Asset Management's Ultragenyx Pharmaceutical position peaked at $6.07M in Q3 2024.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.